Ghent University Academic Bibliography

Your filters: cql: author="Fischer, Matthias" or (type any "bookEditor issueEditor" and editor="Fischer, Matthias")

Add to list
- Conference Paper
- C3
Development of a digital PCR TERT/TERRA quantification assay in neuroblastoma

Pinar Safari, Kimberly Verniers (UGent) , Lisa Werr, Christoph Bartenhagen, Nickolas Johns Ramirez (UGent) , Anneleen Decock (UGent) , Bram De Wilde (UGent) , Matthias Fischer and Jo Vandesompele (UGent)

(2025) Advances in Neuroblastoma Research (ANR) Meeting 2025, Abstracts.
Add to list
A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

Steven G. DuBois, Chitose Ogawa, Lucas Moreno, Yaël P. Mossé, Matthias Fischer, Anne L. Ryan, Kieuhoa T. Vo, Bram De Wilde (UGent) , Alba Rubio‐San‐Simon, Margaret E. Macy, et al.

(2025) CANCER. 131(4).
Add to list
- Journal Article
- A1
- open access
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Carolina de Carvalho Nunes, Lisa Depestel (UGent) , Liselot Mus (UGent) , Kaylee M. Keller, Louis Delhaye (UGent) , Amber Louwagie, Muhammad Rishfi (UGent) , Alex Whale, Neesha Kara, Simon R. Andrews, et al.

(2022) SCIENCE ADVANCES. 8(28).
Add to list
Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy

Jingwei Chen, Christopher Nelson, Matthew Wong, Andrew E. Tee, Pei Y. Liu, Ting La, Jamie I. Fletcher, Alvin Kamili, Chelsea Mayoh, Christoph Bartenhagen, et al.

(2021) CLINICAL CANCER RESEARCH. 27(5). p.1438-1451
Add to list
- Journal Article
- A1
- open access
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Liselot Mus (UGent) , Irina Lambertz (UGent) , Shana Claeys (UGent) , Candy Kumps (UGent) , Wouter Van Loocke (UGent) , Christophe Van Neste (UGent) , Ganesh Umapathy, Marica Vaapil, Christoph Bartenhagen, Genevieve Laureys (UGent) , et al.

(2020) SCIENTIFIC REPORTS. 10.
Add to list
Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Lucas Moreno, Giuseppe Barone, Steven G. DuBois, Jan Molenaar, Matthias Fischer, Johannes Schulte, Angelika Eggert, Gudrun Schleiermacher, Franki Speleman (UGent) , Louis Chesler, et al.

(2020) EUROPEAN JOURNAL OF CANCER. 136. p.52-68
Add to list
- Journal Article
- A1
- open access
Phase I dose‐escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors

François Doz, Franco Locatelli, André Baruchel, Nicolas Blin, Barbara De Moerloose (UGent) , Didier Frappaz, Michael Dworzak, Matthias Fischer, Jan Stary, Rene Fuertig, et al.

(2019) PEDIATRIC BLOOD & CANCER. 66(10).
Add to list
- Journal Article
- A1
- open access
Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes

Dries Rombaut, Hua-Sheng Chiu, Bieke Decaesteker (UGent) , Celine Everaert (UGent) , Nurten Yigit (UGent) , Agathe Pelthier, Isabelle Janoueix, Christophe Bartenhagen, Matthias Fischer, Stephen Roberts, et al.

(2019) SCIENTIFIC REPORTS. 9.
Add to list
- Journal Article
- A1
- open access
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35

Pei Y Liu, Andrew E Tee, Giorgio Milazzo, Katherine M Hannan, Jesper Maag, Sujanna Mondal, Bernard Atmadibrata, Nenad Bartonicek, Hui Peng, Nicholas Ho, et al.

(2019) NATURE COMMUNICATIONS. 10.
Add to list
LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis

Carmen Dorneburg, Matthias Fischer, Thomas FE Barth, Wolfgang Mueller-Klieser, Barbara Hero, Judith Gecht, Daniel R Carter, Katleen De Preter (UGent) , Benjamin Mayer, Lisa Christner, et al.

(2018) CLINICAL CANCER RESEARCH. 24(22). p.5772-5783

Academic Bibliography

Development of a digital PCR TERT/TERRA quantification assay in neuroblastoma

A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Phase I dose‐escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors

Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes

The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35

LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis

Contents

Support

Contact